Non-Hodgkin Lymphoma | Specialty

Antibody-Drug Conjugate Impresses in Relapsed/Refractory DLBCL

December 3rd 2018

The addition of a CD79b-targeted antibody-drug conjugate to bendamustine and rituximab more than doubled overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma.

Reduced Treatment Equally Effective in DLBCL

December 2nd 2018

Treating younger patients with low-risk diffuse large B-cell lymphoma with 2 fewer frontline cycles of R-CHOP greatly reduced toxicity without sacrificing efficacy, according to findings from the FLYER trial.

Tisagenlecleucel Benefit Sustained in DLBCL Follow-Up

December 2nd 2018

Tisagenlecleucel continued to demonstrate durable objective response rates with a median of 19 months of follow-up for patients with relapsed or refractory diffuse large B-cell lymphoma, according to updated findings from the phase II JULIET study.

FDA Approves Brentuximab Vedotin for Frontline CD30+ PTCL

November 16th 2018

The FDA has approved brentuximab vedotin for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.

FDA Grants Brentuximab Vedotin Breakthrough Designation for Frontline CD30+ PTCL

November 16th 2018

The FDA has granted brentuximab vedotin a breakthrough therapy designation for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.

Dr. Andreadis Discusses the Role of Ibrutinib in DLBCL

November 14th 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with diffuse large B-cell lymphoma.

Emerging Agents, Strategies Propel Progress in Follicular Lymphoma

November 8th 2018

Novel agents and treatment strategies continue to expand the armamentarium in follicular lymphoma, explains John P. Leonard, MD, in a session at the 36th Annual CFS®.

FDA Grants Selinexor Fast Track Designation for Relapsed/Refractory DLBCL

November 8th 2018

The FDA has granted a fast track designation to selinexor for the treatment of patients with previously treated diffuse large B-cell lymphoma who are ineligible to receive high-dose chemotherapy with stem cell rescue or CAR T-cell therapy.

FDA Approval Sought for Brentuximab Vedotin in Frontline CD30+ PTCL

November 6th 2018

A supplemental biologics license application has been submitted to the FDA for the use of brentuximab vedotin (Adcetris) in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.

Dr. Roschewski on the Use of DA-EPOCH-R in Burkitt Lymphoma

November 2nd 2018

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the use of dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in patients with Burkitt lymphoma.

UCSF Expert Highlights Progress in Lymphoma Landscape

October 29th 2018

Lawrence D. Kaplan, MD, discusses recent updates and next steps in the expanding paradigm of Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma.

Future Directions for CAR-T Therapy

October 29th 2018

Expanding the Role of CAR T in non-Hodgkin Lymphoma

October 29th 2018

CAR-T Post-Infusion Care, Financial Considerations, and Data Management

October 29th 2018

The Production of CAR T Cells for non-Hodgkin Lymphoma

October 29th 2018

The Workflow of CAR-T Administration

October 29th 2018

The Logistics of Building a CAR-T Program

October 29th 2018

Patient Selection for CAR-T Therapy in NHL

October 29th 2018

CAR-T Safety & Post-Treatment Plans

October 29th 2018

Variations Among CAR T Products for NHL

October 29th 2018